

姓名

饒坤銘

現職

義大癌治療醫院內科副院長

學歷

中山醫學院醫學系 學士

長庚大學臨床醫學研究所碩士

經歷

1999-2018 高雄長庚醫院血液腫瘤科主治醫師

2002-2004 M.D. Anderson Cancer Center, Houston, Texas, U.S.A.,

Department of Molecular and Cellular Oncology , 訪問學者

2005-2013 高雄長庚醫院血液腫瘤科主任

2005-2015 高雄長庚醫院癌症中心執行秘書

2018-至今 義大癌治療醫院血液腫瘤部主治醫師

2018-至今 義大癌治療醫院內科副院長

2023-至今 教育部部定教授

專科執照

1. 中華民國內科醫學會專科醫師
2. 台灣癌症醫學會腫瘤內科醫師
3. 乳房醫學會專科醫師
4. 癌症安寧緩和醫學會專科醫師

專長

1. 癌症診斷與治療
2. 轉譯醫學研究
3. 癌症臨床試驗
4. 癌症精準醫療

論文發表

1. Tackling similarities and differences in global practice guidelines for gastric cancer: a review on the latest Taiwan guidelines with Asia-Pacific, European and US guidelines. Yen CC; Wu IC; Yu CC; Chen MH; Chiang NJ; Fang WL; Chen KH; Chen CC; Hong TC; Chen YC; Wong MW; Chan DC; Chen IS; Chen YY; Liu YW; Wu JM; Chou WC; Yang CK; Hsu JT; Yeh TS; Bai LY; Chang YF; Hsieh YY; Peng CM; Wang JY; Hsiao HH; Chen LT; **Rau KM**; Yen CJ; Chen JS; Shan YS. Gastric Cancer. 2026 May 18.
2. Validation of the Chinese Version Breakthrough Pain Assessment Tool in Cancer Patients. Chen LJ; **Rau KM**; Lin PC; Liu Y; Chou PL. Pain Manag Nurs. 2026 Apr;27(2):e207-e215.
3. Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. Loibl S; Park YH; Shao

Z; Huang CS; Barrios C; Abraham J; Prat A; Niikura N; Im SA; Li W; Li H; Wang Y; Yao H; Kim SB; Geng CZ; Rodriguez Pantigoso W; Ramírez Godinez FJ; Song C; Ching Chang Y; Antoniazzi A; Chen SC; Li Z; Nowecki Z; Lim J; Mathias E; Sato Y; Lu W; Abdel-Monem H; Untch M; Geyer CE Jr; DESTINY-Breast05 Trial Investigators. *N Engl J Med.* 2026 Feb 26;394(9):845-857

4. SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217 Chiang NJ, Su YY, Ho IW, Bai LY, Li CP, Chen JS, Hsiao CF, Tsou HH, Hsu C, Chiu TJ, Hsieh YY, **Rau KM**, Ho CL, Shan YS, Chen LT. *European Journal of Cancer*, 2026 Feb;235:116229.
5. Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer (DESTINY-Breast05)Loibl S, Park YH, Shao Z, Huang CS, Barrios C, Abraham J, Prat A, Niikura N, Im SA, et al.; DESTINY-Breast05 Trial Investigators. *New England Journal of Medicine*, 2026 Feb;394(9):845-857.
6. Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: a real-world study in breast cancer patients in Taiwan.Wang SC, Shen YC, Pan MR, Ou-Yang F, Liao TY, Liu LC, **Rau KM**, Lu LS, Huang CC, Dai MS, Lu YS, Chang HW, Chang H, Chang KP, Wang J, Tsai CJ, Chou IW, Li HW, Cheng WC, Li TC, Cha TL, Liao GS, Chiu CF, Huang CS, Tseng LM, Chiou JF, Sheen-Chen SM, Hou MF, Hung MC. *Cancer Lett.* 2025 Jul 10;631:217912.
7. Astragalus polysaccharides improve adjuvant chemotherapy-induced fatigue for patients with early breast cancer.
Shen WC, Chen SC, Wang CH, Hung CM, Peng MT, Liu CT, Chang YS, Kuo WL, Chou HH, Yeh KY, Wu TH, Wu CF, Chang PH, Huang YM, Yu CC, Lee CH, **Rau KM**.*Sci Rep.* 2024 Oct 28;14(1):25690. doi:
8. Luteolin (LUT) Induces Apoptosis and Regulates Mitochondrial Membrane Potential to Inhibit Cell Growth in Human Cervical Epidermoid Carcinoma Cells (Ca Ski).
Pei SN, Lee KT, **Rau KM**, Lin TY, Tsai TH, Hsu YC.*Biomedicines.* 2024 Oct 14;12(10):2330.
9. Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression.
Liu TH, Chen SC, **Rau KM**, Lu LC, Lin PT, Su YY, Teng W, Lai SW, Yeh RH, Kao TM, Lee PC, Wu CJ, Chen CH, Hsu CH, Lin SM, Huang YH, Chen LT, Cheng AL, Shen YC; Taiwan Liver Cancer Association Research Group (TRG).*Liver Cancer.* 2024 Feb 1;13(5):509-521.
10. Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with. trifluridine/tipiracil or regorafenib. Hsiao KY, Chen

HP, **Rau KM**, Liu KW, Shia BC, Chang WS, Liang HY, Hsieh MC. *Oncologist*. 2024 Dec 6;29(12):e1669-e1679.

11. Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab. Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, Eguchi S, Yoshizumi T, Itoh S, Nakamura N, Kosaka H, Kaibori M, Ishii T, Hatano E, Ogawa C, Naganuma A, Kakizaki S, Cheng CH, Lin PT, Su YY, Chuang CH, Lu LC, Wu CJ, Wang HW, **Rau KM**, Hsu CH, Lin SM, Huang YH, Hernandez S, Finn RS, Kudo M, Cheng AL. *J Clin Oncol*. 2024 Dec;42(34):4060-4070.
12. Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial.
Chen TW, Dai MS, Tseng LM, Chen SC, Chao TY, Chao TC, Chang YC, Chiu CF, Liu CT, Lin CH, Liu CY, Chen YF, Chang DY, Yu JC, **Rau KM**, Hsieh YY, Shen SC, Huang SM, Cheng AL, Lu YS. *JAMA Oncol*. 2024 Mar 1;10(3):325-334
13. Management of cancer-related fatigue in Taiwan: an evidence-based consensus for screening, assessment and treatment. **Rau KM**, Shun SC, Hung SH, Chou HL, Ho CL, Chao TC, Liu CY, Lien CT, Hong MY, Wu CJ, Tsai LY, Jane SW, Hsieh RK. *Jpn J Clin Oncol*. 2023 Jan 6;53(1):46-5
14. Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options? Rajappa S, **Rau KM**, Dattatreya PS, Ramaswamy A, Fernandes P, Pruthi A, Cheng R, Lukanowski M, Huang YH. *World J Hepatol*. 2022 Jun 27;14(6):1074-1086
15. An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer. Hsieh MC, **Rau KM**, Lin SE, Liu KW, Chiu CC, Chen CI, Song LC, Chen HP. *Front Oncol*. 2022 May 19;12:867546.
16. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Kudo M, Finn RS, Morimoto M, **Rau KM**, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX. *Liver Cancer*. 2021 Jul 12;10(5):451-460.
17. Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. Dai MS, Feng YH, Chen SW, Masuda N, Yau T, Chen ST, Lu YS, Yap YS, Ang PCS, Chu SC, Kwong A, Lee KS, Ow S, Kim SB, Lin J, Chung HC, Ngan R, Kok VC, **Rau KM**, Sangai T, Ng TY, Tseng LM, Bryce R, Bebbchuk J, Chen MC, Hou MF. *Breast Cancer Res Treat*. 2021 Oct;189(3):665-676.

18. A Novel Combination of Bevacizumab with Chemotherapy Improves Therapeutic Effects for Advanced Biliary Tract Cancer: A Retrospective, Observational Study.
 19. Pei SN, Liao CK, Chen YS, Tseng CH, Hung CM, Chiu CC, Hsieh MC, Tsai YF, Liao HY, Liu WC, **Rau KM**. *Cancers (Basel)*. 2021 Jul 29;13(15):3831.
 20. Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study. Liu CT, Hsieh MC, Su YL, Hung CM, Pei SN, Liao CK, Tsai YF, Liao HY, Liu WC, Chiu CC, Wu SC, Wang SH, Wei CT, **Rau KM**. *J Cancer*. 2021 Jul 3;12(17):5355-5364
 21. Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. Ryoo BY, Cheng AL, Ren Z, Kim TY, Pan H, **Rau KM**, Choi HJ, Park JW, Kim JH, Yen CJ, Lim HY, Zhou D, Straub J, Scheele J, Berghoff K, Qin S. *Br J Cancer*. 2021 Jul;125(2):200-208.
 22. Integrin $\alpha\text{IIb}\beta 3$ outside-in signaling activates human platelets through serine 24 phosphorylation of Disabled-2. Tsai HJ, Cheng JC, Kao ML, Chiu HP, Chiang YH, Chen DP, **Rau KM**, Liao HR, Tseng CP. *Cell Biosci*. 2021 Feb 8;11(1):32
 23. S1 versus Doublet Regimens as Adjuvant Chemotherapy in Patients with Advanced Gastric Cancer after Radical Surgery with D2 Dissection-A Propensity Score Matching Analysis. Hsieh MC, Wang SH, Wei CT, Chen CY, Chen YY, Pei SN, Tsai YF, **Rau KM**. *Cancers (Basel)*. 2020 Aug 23;12(9):2384.
 24. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. Desai J, Deva S, Lee JS, Lin CC, Yen CJ, Chao Y, Keam B, Jameson M, Hou MM, Kang YK, Markman B, Lu CH, **Rau KM**, Lee KH, Horvath L, Friedlander M, Hill A, Sandhu S, Barlow P, Wu CY, Zhang Y, Liang L, Wu J, Paton V, Millward M. *J Immunother Cancer*. 2020 Jun;8(1):e000453
 25. A nationwide survey of fatigue in cancer patients in Taiwan: an unmet need.**Rau KM**, Shun SC, Chiou TJ, Lu CH, Ko WH, Lee MY, Huang WT, Yeh KH, Chang CS, Hsieh. RK. *Jpn J Clin Oncol*. 2020 Jun 10;50(6):693-700.
 26. Improvement of Paclitaxel-Associated. Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis.Chou PL, Huang YP, Cheng MH, **Rau KM**, Fang YP. *Int J Nanomedicine*. 2020 Mar 12;15:1731-1743.
 27. Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response. **Rau KM**, Liu CT, Hsiao YC, Hsiao KY, Wang TM, Hung WS, Su YL, Liu WC, Wang CH, Hsu. HL, Chuang PH, Cheng JC, Tseng CP. *J Clin Med*. 2020 Jan 10;9(1):188.
- Taiwan nutritional consensus on the nutrition management for gastric cancer patients receiving gastrectomy. Hsu PI, Chuah SK, Lin JT, Huang SW, Lo JC, **Rau KM**, Chen IS, Hsu

HY, Sheu BS, Chang WK, Wu DC. J Formos Med Assoc. 2019 Dec 16:S0929-6646(19)30013-0.

28. Comparative Study of the Safety and Efficacy of First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma. Huang SY, Wu CC, Hsieh MC, **Rau KM**, Chiang PH, Sung MT, Luo HL, Huang CC, Huang CH, Liu JM, Su HY. Oncology. 2020;98(3):146-153.
29. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. Bang YJ, Li CP, Lee KH, Chiu CF, Park JO, Shan YS, Kim JS, Chen JS, Shim HJ, **Rau KM**, Choi HJ, Oh DY, Belanger B, Chen LT. Cancer Sci. 2020 Feb;111(2):513-527.
30. Presence of Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI): A Nationwide, Population-Based Cohort Study. **Rau KM**, Wu CC, Lee WC, Hsieh MC, Liu JS, Chen YY, Su HY. J Clin Med. 2019 Jul 12;8(7):1024.
31. Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Lee HH, Wang YN, Xia W, Chen CH, **Rau KM**, Ye L, Wei Y, Chou CK, Wang SC, Yan M, Tu CY, Hsia TC, Chiang SF, Chao KSC, Wistuba II, Hsu JL, Hortobagyi GN, Hung MC. Cancer Cell. 2019 Aug 12;36(2):168-178 Cancer Cell. 2019 Aug 12;36(2):168-178
32. Performance Status as A Predictive Factor for Cancer-Related Fatigue Treatment with Astragalus Polysaccharides (PG2) Injection-A Double Blind, Multi-Center, Randomized Phase IV Study. Karnofsky Wang CH, Lin CY, Chen JS, Ho CL, **Rau KM**, Tsai JT, Chang CS, Yeh SP, Cheng CF, Lai YL. Cancers (Basel) 2019 Jan 22;11(2):128,
33. REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, **Rau KM**, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; Lancet Oncol. 2019 Feb;20(2):282-296.
34. A nationwide survey of adherence to analgesic drugs among cancer patients in Taiwan: prevalence, determinants, and impact on quality of life. Chou WC, Chen JS, Hung CY, Lu CH, Shao YY, Chiou TJ, Sung YC, **Rau KM**, Yen CJ, Yeh SP, Liu TC, Wu MF, Lee MY, Yu

MS, Hwang WL, Lai PY, Chang CS, Hsieh RK. Support Care Cancer. 2019 Aug;27(8):2857-2867.

35. A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients Hsu HC, Chou WC, Kuan FC, Lee KD, **Rau KM**, Huang JS, Yang TS.. Cancer Manag Res. 2018 Nov 21;10:6061-6070.
36. Patients with head and neck cancer may need more intensive pain management to maintain daily functioning: a multi-center study. Cho SF, **Rau KM**, Shao YY, Yen CJ, Wu MF, Chen JS, Chang CS, Yeh SP, Chiou TJ, Hsieh RK, Lee MY, Sung YC, Lee KD, Lai PY, Yu MS, Hwang WL, Liu TC. Support Care Cancer. 2019 May;27(5):1663-1672.
37. Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan. **Rau KM**, Ou-Yang F, Chao TC, Kuo YL, Cheng TF, Chao TY, Chen DR, Tzeng YD, Wang BW, Liu CY, Hu MH, Lu YC, Ou WJ, Kuo CH, Chuang CH, Kan JY, Chen FM, Hou MF. Breast Cancer Res Treat. 2018 Aug;170(3):583-591. doi: 10.1007/s10549-018-4778-y. Epub 2018 Apr 5. PMID: 29623575
38. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Kamphuisen PW, Lee AYY, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. J Thromb Haemost. 2018 Jun;16(6):1069-1077. doi: 10.1111/jth.14007. Epub 2018 Apr 17. PMID: 29573330
39. Patient-clinician relationship seems to affect adherence to analgesic use in cancer patients: a cross sectional study in a Taiwanese population. Chou PL, **Rau KM**, Yu TW, Huang TL, Sun JL, Wang SY, Lin CC. Int J Qual Health Care. 2017 Nov 1;29(7):935-940. doi: 10.1093/intqhc/mzx134.
40. Cancer-related pain: a nationwide survey of patients' treatment modification and satisfaction in Taiwan. **Rau KM**, Chen JS, Wu HB, Lin SF, Huang ML, Tai CJ, Hwang WL, Lu YC, Wang CC, Kuen Hsieh R. Jpn J Clin Oncol. 2017 Nov 1;47(11):1060-1065. doi: 10.1093/jjco/hyx124. PMID: 28973687 **Free PMC Article**
41. High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy. **Rau KM**, Su YL, Li SH, Hsieh MC, Wu SC, Chou FF, Chiu TJ, Chen YH, Liu CT. Mol Med Rep. 2017 Nov;16(5):7185-7190. doi: 10.3892/mmr.2017.7555. Epub 2017 Sep 20.
42. Gender Difference in Cancer Patients' Adherence to Analgesics and Related Outcomes of Pain Management. Chou PL, Fang SY, Sun JL, **Rau KM**, Lee BO. Cancer Nurs. 2017 Jul 27. doi: 10.1097/NCC.0000000000000532. [Epub ahead of print] PMID: 28753193

43. Impact of Undertreatment of Cancer Pain With Analgesic Drugs on Patient Outcomes: A Nationwide Survey of Outpatient Cancer Patient Care in Taiwan. Shen WC, Chen JS, Shao YY, Lee KD, Chiou TJ, Sung YC, **Rau KM**, Yen CJ, Liao YM, Liu TC, Wu MF, Lee MY, Yu MS, Hwang WL, Lai PY, Chang CS, Chou WC, Hsieh RK. *J Pain Symptom Manage*. 2017 Jul;54(1):55-65.e1. doi: 10.1016/j.jpainsymman.2017.02.018. Epub 2017 May 4. PMID: 28479410
44. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis. Kuo YH, Wu IP, Wang JH, Hung CH, **Rau KM**, Chen CH, Kee KM, Hu TH, Lu SN. *Invest New Drugs*. 2018 Apr;36(2):307-314. doi: 10.1007/s10637-017-0468-6. Epub 2017 May 2. PMID: 28466374
45. Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer. Adiwijaya BS, Kim J, Lang I, Csösz T, Cubillo A, Chen JS, Wong M, Park JO, Kim JS, **Rau KM**, Melichar B, Gallego JB, Fitzgerald J, Belanger B, Molnar I, Ma WW. *Clin Pharmacol Ther*. 2017 Dec;102(6):997-1005. doi: 10.1002/cpt.720. Epub 2017 Jun 5.
46. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. Kuo YH, Wang JH, Hung CH, **Rau KM**, Wu IP, Chen CH, Kee KM, Hu TH, Lu SN. *J Gastroenterol Hepatol*. 2017 Dec;32(12):1975-1981. doi: 10.1111/jgh.13783.
47. The effects of hospice-shared care for gastric cancer patients. Huang KS, Wang SH, Chuah SK, **Rau KM**, Lin YH, Hsieh MC, Shih LH, Chen YH. *PLoS One*. 2017 Feb 3;12(2):e0171365. doi: 10.1371/journal.pone.0171365. eCollection 2017.
48. Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma.. Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer. Adiwijaya BS, Kim J, Lang I, Csösz T, Cubillo A, Chen JS, Wong M, Park JO, Kim JS, **Rau KM**, Melichar B, Gallego JB, Fitzgerald J, Belanger B, Molnar I, Ma WW. *Clin Pharmacol Ther*. 2017 Dec;102(6):997-1005.
49. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. Kuo YH, Wang JH, Hung CH, **Rau KM**, Wu IP, Chen CH, Kee KM, Hu TH, Lu SN. *J Gastroenterol Hepatol*. 2017 Dec;32(12):1975-1981
50. Patient-clinician relationship seems to affect adherence to analgesic use in cancer patients: a cross sectional study in a Taiwanese population. Chou PL, **Rau KM**, Yu TW, Huang TL, Sun JL, Wang SY, Lin CC. *Int J Qual Health Care*. 2017 Nov 1;29(7):935-940.

51. Cancer-related pain: a nationwide survey of patients' treatment modification and satisfaction in Taiwan. **Rau KM**, Chen JS, Wu HB, Lin SF, Huang ML, Tai CJ, Hwang WL, Lu YC, Wang CC, Kuen Hsieh R. *Jpn J Clin Oncol*. 2017 Nov 1;47(11):1060-1065.
52. High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy.
Rau KM, Su YL, Li SH, Hsieh MC, Wu SC, Chou FF, Chiu TJ, Chen YH, Liu CT. *Mol Med Rep*. 2017 Nov;16(5):7185-7190.
53. Gender Difference in Cancer Patients' Adherence to Analgesics and Related Outcomes of Pain Management.
Chou PL, Fang SY, Sun JL, **Rau KM**, Lee BO. *Cancer Nurs*. 2017 Jul 27.
54. Impact of Undertreatment of Cancer Pain with Analgesic Drugs on Patient Outcomes: A Nationwide. Survey of Outpatient Cancer Patient Care in Taiwan. Shen WC, Chen JS, Shao YY, Lee KD, Chiou TJ, Sung YC, **Rau KM**, Yen CJ, Liao YM, Liu TC, Wu MF, Lee MY, Yu MS, Hwang WL, Lai PY, Chang CS, Chou WC, Hsieh RK. *J Pain Symptom Manage*. 2017 May 4
55. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis. Kuo YH, Wu IP, Wang JH, Hung CH, **Rau KM**, Chen CH, Kee KM, Hu TH, Lu SN.
Invest New Drugs. 2017 May 2.
56. Population pharmacokinetics of liposomal irinotecan in patients with cancer.
Adiwijaya B, Kim J, Lang I, Csösz T, Cubillo A, Chen JS, Wong M, Park JO, Kim JS, **Rau KM**, Melichar. B, Gallego J, Fitzgerald J, Belanger B, Molnar I, Ma WW *Clin Pharmacol Ther*. 2017 Apr 26.
57. The ALBI grade predicts the prognosis of patients with advanced hepatocellular carcinoma received. sorafenib. Kuo YH, Wang JH, Hung CH, **Rau KM**, Wu IP, Chen CH, Kee KM, Hu TH, Lu SN. *J Gastroenterol Hepatol*. 2017 Mar 11.
58. The effects of hospice-shared care for gastric cancer patients. Huang KS, Wang SH, Chuah SK, **Rau KM**, Lin YH, Hsieh MC, Shih LH, Chen YH. *PLoS One*. 2017 Feb 3;12(2):e0171365
59. Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma. Su YL, Hsieh MC, Chiang PH, Sung MT, Lan J, Luo HL, Huang CC, Huang CH, Tang Y, **Rau KM**. *PLoS One*. 2017 Jan 11;12(1):e0169657.

60. A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone Metastases. Chen YM, Fang YT, Lai CH, **Rau KM**, Huang CH, Chang HC, Chao TY, Tseng CC, Fang WF, Wang CC, Chen YC, Chung YH, Wang YH, Su MC, Liu SF, Huang KT, Chen HC, Chang YC, Chang YP, Lin MC. PLoS One. 2016 Dec 8;11(12):e0167923.
61. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors. Chen YM, Lai CH, **Rau KM**, Huang CH, Chang HC, Chao TY, Tseng CC, Fang WF, Chung YH, Wang YH, Su MC, Huang KT, Liu SF, Chen HC, Chang YC, Chang YP, Wang CC, Lin MC. BMC Cancer. 2016 Nov 8;16(1):868
62. A preliminary randomised controlled study of short-term Antrodia cinnamomea treatment combined with chemotherapy for patients with advanced cancer. Tsai MY, Hung YC, Chen YH, Chen YH, Huang YC, Kao CW, Su YL, Chiu HH, **Rau KM**. BMC Complement Altern Med. 2016 Aug 26;16(1):322. doi:
63. Truth-Telling in Taiwanese Cancer Care: Patients' and Families' Preferences and their Experiences of Doctors' Practices. Tang WR, Hong JH, **Rau KM**, Wang CH, Juang YY, Lai CH, Fujimori. M, Fang CK. Psychooncology. 2016 Aug 19. doi: 10.1002/pon.4257.
64. Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors. Chen YM, Lai CH, **Rau KM**, Huang CH, Chang HC, Chao TY, Tseng CC, Fang WF, Chen YC, Chung YH, Wang YH, Su MC, Huang KT, Liu SF, Chen HC, Chang YC, Chang YP, Wang CC, Lin MC. Lung Cancer. 2016 Aug;98:99-105.
65. A Prognostic Model Using Inflammation- and Nutrition-Based Scores in Patients With Metastatic Gastric Adenocarcinoma Treated With Chemotherapy. Hsieh MC, Wang SH, Chuah SK, Lin YH, Lan J, **Rau KM**. Medicine (Baltimore). 2016 Apr;95(17):e3504.

NAME

Kun-Ming Rau

CURRENT POSITION TITLE

Vice Superintendent of E-Da Cancer Hospital

EDUCATION/TRAINING

Chung-Shag Medical University, Collage of Medicine, M.D. degree

Chang-Gung University Graduate Institute of Clinical Medical Science, MPH

M.D. Anderson Cancer Center, Houston, Texas, U.S.A., Department of Molecular and Cellular Oncology ,
Visiting Scientist

Employment

Resident 1994-1997	Department of Internal Medicine Chang-Gung Memorial Hospital, Kaohsiung Medical Center
Fellow/Instructor 1997-1999	Division of Hematology-Oncology Chang-Gung Memorial Hospital, Lin-Ko and Kaohsiung Medical Center
Attending Physician 1999—2018 2018-	Division of Hematology-Oncology Chang-Gung Memorial Hospital, Kaohsiung Medical Center Department of Hematology-Oncology, E-Da Cancer Hospital
Physician Scientist 2002-2004	Molecular and Cellular Oncology Department M.D.Anderson Cancer Center, Houston, Texas, USA Visiting Scientist
Division Chief 2005— 2013 2006-2008	Division of Hematology-Oncology, Department of Internal Medicine Chang-Gung Memorial Hospital, Kaohsiung Medical Center Chief of Cancer Preventive Center Chang-Gung Memorial Hospital, Kaohsiung Medical Center
Vice Superintendent. 2018- Associate professor 2018-2023 Professor 2023-present	E-Da Cancer Hospital College of Medicine , I-Shou University College of Medicine , I-Shou University

Honors

2008 Cancer Center wan the first class grade.

2005-present More than 200 invited speeches at cancer-related society.

Major Interesting

1. Cancer diagnosis and treatment plan design
 2. Systemic anti-cancer therapies, chemotherapy, target therapy, hormone therapy and immunotherapy
-

3. Palliative care of cancer-related symptoms

Professional Memberships

1997-present Member, Society of Internal Medicine

1999-present Member, Society of Medical Oncology

2005-present Member, Taiwan Society of Cancer Palliative Medicine

2005-present Member, Breast Cancer Society

Professional Certifications

1. Internal Medicine

2. Medical Oncology

3. Breast cancer Specialist

4. Advanced Cardiac Life Support

Peer-reviewed publications

1. Tackling similarities and differences in global practice guidelines for gastric cancer: a review on the latest Taiwan guidelines with Asia-Pacific, European and US guidelines. Yen CC; Wu IC; Yu CC; Chen MH; Chiang NJ; Fang WL; Chen KH; Chen CC; Hong TC; Chen YC; Wong MW; Chan DC; Chen IS; Chen YY; Liu YW; Wu JM; Chou WC; Yang CK; Hsu JT; Yeh TS; Bai LY; Chang YF; Hsieh YY; Peng CM; Wang JY; Hsiao HH; Chen LT; **Rau KM**; Yen CJ; Chen JS; Shan YS. *Gastric Cancer*. 2026 May 18.
 2. Validation of the Chinese Version Breakthrough Pain Assessment Tool in Cancer Patients. Chen LJ; **Rau KM**; Lin PC; Liu Y; Chou PL. *Pain Manag Nurs*. 2026 Apr;27(2):e207-e215.
 3. Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. Loibl S; Park YH; Shao Z; Huang CS; Barrios C; Abraham J; Prat A; Niikura N; Im SA; Li W; Li H; Wang Y; Yao H; Kim SB; Geng CZ; Rodriguez Pantigoso W; Ramirez Godinez FJ; Song C; Ching Chang Y; Antoniazzi A; Chen SC; Li Z; Nowecki Z; Lim J; Mathias E; Sato Y; Lu W; Abdel-Monem H; Untch M; Geyer CE Jr; DESTINY-Breast05 Trial Investigators. *N Engl J Med*. 2026 Feb 26;394(9):845-857
 4. SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217 Chiang NJ, Su YY, Ho IW, Bai LY, Li CP, Chen JS, Hsiao CF, Tsou HH, Hsu C, Chiu TJ, Hsieh YY, **Rau KM**, Ho CL, Shan YS, Chen LT. *European Journal of Cancer*, 2026 Feb;235:116229.
 5. Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer (DESTINY-Breast05)Loibl S, Park YH, Shao Z, Huang CS, Barrios C, Abraham J, Prat A, Niikura N, Im SA, et al.; DESTINY-Breast05 Trial Investigators. *New England Journal of Medicine*, 2026 Feb;394(9):845-857.
 6. Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: a real-world study in breast cancer patients in Taiwan.Wang SC, Shen YC, Pan MR, Ou-Yang F, Liao TY, Liu LC, **Rau KM**, Lu LS, Huang CC, Dai MS, Lu YS, Chang HW, Chang H, Chang KP, Wang J, Tsai CJ, Chou IW, Li HW, Cheng WC, Li TC, Cha TL, Liao GS, Chiu CF, Huang CS, Tseng LM, Chiou JF, Sheen-Chen SM, Hou MF, Hung MC. *Cancer Lett*. 2025 Jul 10;631:217912.
 7. Astragalus polysaccharides improve adjuvant chemotherapy-induced fatigue for patients with early breast cancer. Shen WC, Chen SC, Wang CH, Hung CM, Peng MT, Liu CT, Chang YS, Kuo WL, Chou HH, Yeh KY, Wu TH, Wu CF, Chang PH, Huang YM, Yu CC, Lee CH, **Rau KM**.*Sci Rep*. 2024 Oct 28;14(1):25690. doi:
 8. Luteolin (LUT) Induces Apoptosis and Regulates Mitochondrial Membrane Potential to Inhibit Cell Growth in Human Cervical Epidermoid Carcinoma Cells (Ca Ski).
Pei SN, Lee KT, **Rau KM**, Lin TY, Tsai TH, Hsu YC.*Biomedicines*. 2024 Oct 14;12(10):2330.
 9. Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression.
Liu TH, Chen SC, **Rau KM**, Lu LC, Lin PT, Su YY, Teng W, Lai SW, Yeh RH, Kao TM, Lee PC, Wu CJ, Chen CH, Hsu CH, Lin SM, Huang YH, Chen LT, Cheng AL, Shen YC; Taiwan Liver Cancer Association Research Group (TRG).*Liver Cancer*. 2024 Feb 1;13(5):509-521.
 10. Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with. trifluridine/tipiracil or regorafenib. Hsiao KY, Chen HP, **Rau KM**, Liu KW, Shia BC, Chang WS, Liang HY, Hsieh MC. *Oncologist*. 2024 Dec 6;29(12):e1669-e1679.
-

11. Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab. Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, Eguchi S, Yoshizumi T, Itoh S, Nakamura N, Kosaka H, Kaibori M, Ishii T, Hatano E, Ogawa C, Naganuma A, Kakizaki S, Cheng CH, Lin PT, Su YY, Chuang CH, Lu LC, Wu CJ, Wang HW, **Rau KM**, Hsu CH, Lin SM, Huang YH, Hernandez S, Finn RS, Kudo M, Cheng AL. *J Clin Oncol*. 2024 Dec;42(34):4060-4070.
12. Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial.
Chen TW, Dai MS, Tseng LM, Chen SC, Chao TY, Chao TC, Chang YC, Chiu CF, Liu CT, Lin CH, Liu CY, Chen YF, Chang DY, Yu JC, **Rau KM**, Hsieh YY, Shen SC, Huang SM, Cheng AL, Lu YS. *JAMA Oncol*. 2024 Mar 1;10(3):325-334
13. Management of cancer-related fatigue in Taiwan: an evidence-based consensus for screening, assessment and treatment. **Rau KM**, Shun SC, Hung SH, Chou HL, Ho CL, Chao TC, Liu CY, Lien CT, Hong MY, Wu CJ, Tsai LY, Jane SW, Hsieh RK. *Jpn J Clin Oncol*. 2023 Jan 6;53(1):46-5
14. Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options? Rajappa S, **Rau KM**, Dattatreya PS, Ramaswamy A, Fernandes P, Pruthi A, Cheng R, Lukanowski M, Huang YH. *World J Hepatol*. 2022 Jun 27;14(6):1074-1086
15. An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer. Hsieh MC, **Rau KM**, Lin SE, Liu KW, Chiu CC, Chen CI, Song LC, Chen HP. *Front Oncol*. 2022 May 19;12:867546.
16. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Kudo M, Finn RS, Morimoto M, **Rau KM**, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX. *Liver Cancer*. 2021 Jul 12;10(5):451-460.
17. Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. Dai MS, Feng YH, Chen SW, Masuda N, Yau T, Chen ST, Lu YS, Yap YS, Ang PCS, Chu SC, Kwong A, Lee KS, Ow S, Kim SB, Lin J, Chung HC, Ngan R, Kok VC, **Rau KM**, Sangai T, Ng TY, Tseng LM, Bryce R, Bebhuk J, Chen MC, Hou MF. *Breast Cancer Res Treat*. 2021 Oct;189(3):665-676.
18. A Novel Combination of Bevacizumab with Chemotherapy Improves Therapeutic Effects for Advanced Biliary Tract Cancer: A Retrospective, Observational Study.
19. Pei SN, Liao CK, Chen YS, Tseng CH, Hung CM, Chiu CC, Hsieh MC, Tsai YF, Liao HY, Liu WC, **Rau KM**. *Cancers (Basel)*. 2021 Jul 29;13(15):3831.
20. Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study. Liu CT, Hsieh MC, Su YL, Hung CM, Pei SN, Liao CK, Tsai YF, Liao HY, Liu WC, Chiu CC, Wu SC, Wang SH, Wei CT, **Rau KM**. *J Cancer*. 2021 Jul 3;12(17):5355-5364
21. Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. Ryoo BY, Cheng AL, Ren Z, Kim TY, Pan H, **Rau KM**, Choi HJ, Park JW, Kim JH, Yen CJ, Lim HY, Zhou D, Straub J, Scheele J, Berghoff K, Qin S. *Br J Cancer*. 2021 Jul;125(2):200-208.
22. Integrin $\alpha\text{IIb}\beta 3$ outside-in signaling activates human platelets through serine 24 phosphorylation of Disabled-2. Tsai HJ, Cheng JC, Kao ML, Chiu HP, Chiang YH, Chen DP, **Rau KM**, Liao HR, Tseng CP. *Cell Biosci*. 2021 Feb 8;11(1):32
23. S1 versus Doublet Regimens as Adjuvant Chemotherapy in Patients with Advanced Gastric Cancer after Radical Surgery with D2 Dissection-A Propensity Score Matching Analysis. Hsieh MC, Wang SH, Wei CT, Chen CY, Chen YY, Pei SN, Tsai YF, **Rau KM**. *Cancers (Basel)*. 2020 Aug 23;12(9):2384.
24. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. Desai J, Deva S, Lee JS, Lin CC, Yen CJ, Chao Y, Keam B, Jameson M, Hou MM, Kang YK, Markman B, Lu CH, **Rau KM**, Lee KH, Horvath L, Friedlander M, Hill A, Sandhu S, Barlow P, Wu CY, Zhang Y, Liang L, Wu J, Paton V, Millward M. *J Immunother Cancer*. 2020 Jun;8(1):e000453
25. A nationwide survey of fatigue in cancer patients in Taiwan: an unmet need.**Rau KM**, Shun SC, Chiou TJ, Lu CH, Ko WH, Lee MY, Huang WT, Yeh KH, Chang CS, Hsieh. RK. *Jpn J Clin Oncol*. 2020 Jun 10;50(6):693-700.
26. Improvement of Paclitaxel-Associated. Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis.Chou PL, Huang YP, Cheng MH, **Rau KM**, Fang YP. *Int J Nanomedicine*. 2020 Mar 12;15:1731-1743.

27. Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response. **Rau KM**, Liu CT, Hsiao YC, Hsiao KY, Wang TM, Hung WS, Su YL, Liu WC, Wang CH, Hsu. HL, Chuang PH, Cheng JC, Tseng CP. *J Clin Med*. 2020 Jan 10;9(1):188.
Taiwan nutritional consensus on the nutrition management for gastric cancer patients receiving gastrectomy. Hsu PI, Chuah SK, Lin JT, Huang SW, Lo JC, **Rau KM**, Chen IS, Hsu HY, Sheu BS, Chang WK, Wu DC. *J Formos Med Assoc*. 2019 Dec 16;S0929-6646(19)30013-0.
28. Comparative Study of the Safety and Efficacy of First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma. Huang SY, Wu CC, Hsieh MC, **Rau KM**, Chiang PH, Sung MT, Luo HL, Huang CC, Huang CH, Liu JM, Su HY. *Oncology*. 2020;98(3):146-153.
29. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. Bang YJ, Li CP, Lee KH, Chiu CF, Park JO, Shan YS, Kim JS, Chen JS, Shim HJ, **Rau KM**, Choi HJ, Oh DY, Belanger B, Chen LT. *Cancer Sci*. 2020 Feb;111(2):513-527.
30. Presence of Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI): A Nationwide, Population-Based Cohort Study. **Rau KM**, Wu CC, Lee WC, Hsieh MC, Liu JS, Chen YY, Su HY. *J Clin Med*. 2019 Jul 12;8(7):1024.
31. Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Lee HH, Wang YN, Xia W, Chen CH, **Rau KM**, Ye L, Wei Y, Chou CK, Wang SC, Yan M, Tu CY, Hsia TC, Chiang SF, Chao KSC, Wistuba II, Hsu JL, Hortobagyi GN, Hung MC. *Cancer Cell*. 2019 Aug 12;36(2):168-178 *Cancer Cell*. 2019 Aug 12;36(2):168-178
32. Performance Status as A Predictive Factor for Cancer-Related Fatigue Treatment with Astragalus Polysaccharides (PG2) Injection-A Double Blind, Multi-Center, Randomized Phase IV Study. Karnofsky Wang CH, Lin CY, Chen JS, Ho CL, **Rau KM**, Tsai JT, Chang CS, Yeh SP, Cheng CF, Lai YL. *Cancers (Basel)* 2019 Jan 22;11(2):128,
33. REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, **Rau KM**, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; *Lancet Oncol*. 2019 Feb;20(2):282-296.
34. A nationwide survey of adherence to analgesic drugs among cancer patients in Taiwan: prevalence, determinants, and impact on quality of life. Chou WC, Chen JS, Hung CY, Lu CH, Shao YY, Chiou TJ, Sung YC, **Rau KM**, Yen CJ, Yeh SP, Liu TC, Wu MF, Lee MY, Yu MS, Hwang WL, Lai PY, Chang CS, Hsieh RK. *Support Care Cancer*. 2019 Aug;27(8):2857-2867.
35. A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients Hsu HC, Chou WC, Kuan FC, Lee KD, **Rau KM**, Huang JS, Yang TS.. *Cancer Manag Res*. 2018 Nov 21;10:6061-6070.
36. Patients with head and neck cancer may need more intensive pain management to maintain daily functioning: a multi-center study. Cho SF, **Rau KM**, Shao YY, Yen CJ, Wu MF, Chen JS, Chang CS, Yeh SP, Chiou TJ, Hsieh RK, Lee MY, Sung YC, Lee KD, Lai PY, Yu MS, Hwang WL, Liu TC. *Support Care Cancer*. 2019 May;27(5):1663-1672.
37. Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan. **Rau KM**, Ou-Yang F, Chao TC, Kuo YL, Cheng TF, Chao TY, Chen DR, Tzeng YD, Wang BW, Liu CY, Hu MH, Lu YC, Ou WJ, Kuo CH, Chuang CH, Kan JY, Chen FM, Hou MF. *Breast Cancer Res Treat*. 2018 Aug;170(3):583-591. doi: 10.1007/s10549-018-4778-y. Epub 2018 Apr 5. PMID: 29623575
38. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Kamphuisen PW, Lee AYY, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. *J Thromb Haemost*. 2018 Jun;16(6):1069-1077. doi: 10.1111/jth.14007. Epub 2018 Apr 17. PMID: 29573330
39. Patient-clinician relationship seems to affect adherence to analgesic use in cancer patients: a cross sectional study in a Taiwanese population. Chou PL, **Rau KM**, Yu TW, Huang TL, Sun JL, Wang SY, Lin CC. *Int J Qual Health Care*. 2017 Nov 1;29(7):935-940. doi: 10.1093/intqhc/mzx134.
40. Cancer-related pain: a nationwide survey of patients' treatment modification and satisfaction in Taiwan. **Rau KM**, Chen JS, Wu HB, Lin SF, Huang ML, Tai CJ, Hwang WL, Lu YC, Wang CC, Kuen Hsieh R. *Jpn J Clin Oncol*. 2017 Nov 1;47(11):1060-1065. doi: 10.1093/jjco/hyx124. PMID: 28973687 **Free PMC Article**

41. High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy. **Rau KM**, Su YL, Li SH, Hsieh MC, Wu SC, Chou FF, Chiu TJ, Chen YH, Liu CT. *Mol Med Rep*. 2017 Nov;16(5):7185-7190. doi: 10.3892/mmr.2017.7555. Epub 2017 Sep 20.
42. Gender Difference in Cancer Patients' Adherence to Analgesics and Related Outcomes of Pain Management. Chou PL, Fang SY, Sun JL, **Rau KM**, Lee BO. *Cancer Nurs*. 2017 Jul 27. doi: 10.1097/NCC.0000000000000532. [Epub ahead of print] PMID: 28753193
43. Impact of Undertreatment of Cancer Pain With Analgesic Drugs on Patient Outcomes: A Nationwide Survey of Outpatient Cancer Patient Care in Taiwan. Shen WC, Chen JS, Shao YY, Lee KD, Chiou TJ, Sung YC, **Rau KM**, Yen CJ, Liao YM, Liu TC, Wu MF, Lee MY, Yu MS, Hwang WL, Lai PY, Chang CS, Chou WC, Hsieh RK. *J Pain Symptom Manage*. 2017 Jul;54(1):55-65.e1. doi: 10.1016/j.jpainsymman.2017.02.018. Epub 2017 May 4. PMID: 28479410
44. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis. Kuo YH, Wu IP, Wang JH, Hung CH, **Rau KM**, Chen CH, Kee KM, Hu TH, Lu SN. *Invest New Drugs*. 2018 Apr;36(2):307-314. doi: 10.1007/s10637-017-0468-6. Epub 2017 May 2. PMID: 28466374
45. Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer. Adiwijaya BS, Kim J, Lang I, Csösz T, Cubillo A, Chen JS, Wong M, Park JO, Kim JS, **Rau KM**, Melichar B, Gallego JB, Fitzgerald J, Belanger B, Molnar I, Ma WW. *Clin Pharmacol Ther*. 2017 Dec;102(6):997-1005. doi: 10.1002/cpt.720. Epub 2017 Jun 5.
46. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. Kuo YH, Wang JH, Hung CH, **Rau KM**, Wu IP, Chen CH, Kee KM, Hu TH, Lu SN. *J Gastroenterol Hepatol*. 2017 Dec;32(12):1975-1981. doi: 10.1111/jgh.13783.
47. The effects of hospice-shared care for gastric cancer patients. Huang KS, Wang SH, Chuah SK, **Rau KM**, Lin YH, Hsieh MC, Shih LH, Chen YH. *PLoS One*. 2017 Feb 3;12(2):e0171365. doi: 10.1371/journal.pone.0171365. eCollection 2017.
48. Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma.. Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer. Adiwijaya BS, Kim J, Lang I, Csösz T, Cubillo A, Chen JS, Wong M, Park JO, Kim JS, **Rau KM**, Melichar B, Gallego JB, Fitzgerald J, Belanger B, Molnar I, Ma WW. *Clin Pharmacol Ther*. 2017 Dec;102(6):997-1005.
49. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. Kuo YH, Wang JH, Hung CH, **Rau KM**, Wu IP, Chen CH, Kee KM, Hu TH, Lu SN. *J Gastroenterol Hepatol*. 2017 Dec;32(12):1975-1981
50. Patient-clinician relationship seems to affect adherence to analgesic use in cancer patients: a cross sectional study in a Taiwanese population. Chou PL, **Rau KM**, Yu TW, Huang TL, Sun JL, Wang SY, Lin CC. *Int J Qual Health Care*. 2017 Nov 1;29(7):935-940.
51. Cancer-related pain: a nationwide survey of patients' treatment modification and satisfaction in Taiwan. **Rau KM**, Chen JS, Wu HB, Lin SF, Huang ML, Tai CJ, Hwang WL, Lu YC, Wang CC, Kuen Hsieh R. *Jpn J Clin Oncol*. 2017 Nov 1;47(11):1060-1065.
52. High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy. **Rau KM**, Su YL, Li SH, Hsieh MC, Wu SC, Chou FF, Chiu TJ, Chen YH, Liu CT. *Mol Med Rep*. 2017 Nov;16(5):7185-7190.
53. Gender Difference in Cancer Patients' Adherence to Analgesics and Related Outcomes of Pain Management. Chou PL, Fang SY, Sun JL, **Rau KM**, Lee BO. *Cancer Nurs*. 2017 Jul 27.
54. Impact of Undertreatment of Cancer Pain with Analgesic Drugs on Patient Outcomes: A Nationwide. Survey of Outpatient Cancer Patient Care in Taiwan. Shen WC, Chen JS, Shao YY, Lee KD, Chiou TJ, Sung YC, **Rau KM**, Yen CJ, Liao YM, Liu TC, Wu MF, Lee MY, Yu MS, Hwang WL, Lai PY, Chang CS, Chou WC, Hsieh RK. *J Pain Symptom Manage*. 2017 May 4
55. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis. Kuo YH, Wu IP, Wang JH, Hung CH, **Rau KM**, Chen CH, Kee KM, Hu TH, Lu SN. *Invest New Drugs*. 2017 May 2.
56. Population pharmacokinetics of liposomal irinotecan in patients with cancer. Adiwijaya B, Kim J, Lang I, Csösz T, Cubillo A, Chen JS, Wong M, Park JO, Kim JS, **Rau KM**, Melichar. B, Gallego J, Fitzgerald J, Belanger B, Molnar I, Ma WW *Clin Pharmacol Ther*. 2017 Apr 26.
57. The ALBI grade predicts the prognosis of patients with advanced hepatocellular carcinoma received. sorafenib. Kuo YH, Wang JH, Hung CH, **Rau KM**, Wu IP, Chen CH, Kee KM, Hu TH, Lu SN. *J Gastroenterol Hepatol*. 2017 Mar 11.

58. The effects of hospice-shared care for gastric cancer patients. Huang KS, Wang SH, Chuah SK, **Rau KM**, Lin YH, Hsieh MC, Shih LH, Chen YH. *PLoS One*. 2017 Feb 3;12(2):e0171365
59. Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma. Su YL, Hsieh MC, Chiang PH, Sung MT, Lan J, Luo HL, Huang CC, Huang CH, Tang Y, **Rau KM**. *PLoS One*. 2017 Jan 11;12(1):e0169657.
60. A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone Metastases. Chen YM, Fang YT, Lai CH, **Rau KM**, Huang CH, Chang HC, Chao TY, Tseng CC, Fang WF, Wang CC, Chen YC, Chung YH, Wang YH, Su MC, Liu SF, Huang KT, Chen HC, Chang YC, Chang YP, Lin MC. *PLoS One*. 2016 Dec 8;11(12):e0167923.
61. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors. Chen YM, Lai CH, **Rau KM**, Huang CH, Chang HC, Chao TY, Tseng CC, Fang WF, Chung YH, Wang YH, Su MC, Huang KT, Liu SF, Chen HC, Chang YC, Chang YP, Wang CC, Lin MC. *BMC Cancer*. 2016 Nov 8;16(1):868
62. A preliminary randomised controlled study of short-term *Antrodia cinnamomea* treatment combined with chemotherapy for patients with advanced cancer. Tsai MY, Hung YC, Chen YH, Chen YH, Huang YC, Kao CW, Su YL, Chiu HH, **Rau KM**. *BMC Complement Altern Med*. 2016 Aug 26;16(1):322. doi:
63. Truth-Telling in Taiwanese Cancer Care: Patients' and Families' Preferences and their Experiences of Doctors' Practices. Tang WR, Hong JH, **Rau KM**, Wang CH, Juang YY, Lai CH, Fujimori. M, Fang CK. *Psychooncology*. 2016 Aug 19. doi: 10.1002/pon.4257.
64. Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors. Chen YM, Lai CH, **Rau KM**, Huang CH, Chang HC, Chao TY, Tseng CC, Fang WF, Chen YC, Chung YH, Wang YH, Su MC, Huang KT, Liu SF, Chen HC, Chang YC, Chang YP, Wang CC, Lin MC. *Lung Cancer*. 2016 Aug;98:99-105.
65. A Prognostic Model Using Inflammation- and Nutrition-Based Scores in Patients With Metastatic Gastric Adenocarcinoma Treated With Chemotherapy. Hsieh MC, Wang SH, Chuah SK, Lin YH, Lan J, **Rau KM**. *Medicine (Baltimore)*. 2016 Apr;95(17):e3504.